Literature DB >> 21412227

The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia.

Aaron N A Verty1, Megan J Evetts, Geraldine J Crouch, Iain S McGregor, Aneta Stefanidis, Brian J Oldfield.   

Abstract

Anorexia nervosa (AN) is characterized by anhedonia whereby patients experience little pleasure or reward in many aspects of their lives. Reward pathways and the endocannabionid system have been implicated in the mediation of food intake. The potential to exploit these systems to reverse weight loss is investigated in a rodent model of activity-based anorexia (ABA). The effect of subchronic (6 days) Δ(9)-tetrahydrocannabinol (THC) treatment (0.1, 0.5, or 2.0 mg/kg/day) was assessed on chow and high-fat diet (HFD) intake, body weight, running wheel activity (RWA) as well as thermogenesis in brown adipose tissue (BAT) and lipid metabolism in white adipose tissue (WAT). Limited time availability of food and continuous access to running wheels led to anorexia and significantly reduced body weight. THC treatment (0.5 and 2.0 mg/kg/day) transiently stimulated chow intake with a moderate effect on RWA. THC (2.0 mg/kg/day) significantly reduced body weight loss and shifted markers of thermogenesis in BAT and lipid metabolism in WAT in directions consistent with reduced energy expenditure and lipolysis. THC (2.0 mg/kg/day) combined with HFD, produced a transient increase in food intake, reduction in RWA, attenuation of body weight loss, and changes in markers of thermogensis in BAT and lipolysis in the WAT. These changes were significantly greater than those seen in vehicle (HFD), vehicle (chow), and THC (chow)-treated animals. These data show for the first time the effectiveness of the endocannabinoid system in attenuating the weight loss associated with the development of ABA via a mechanism involving reduced energy expenditure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412227      PMCID: PMC3096804          DOI: 10.1038/npp.2011.19

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  70 in total

1.  Increased dopaminergic activity in restricting-type anorexia nervosa.

Authors:  Giuseppe Barbato; Mariateresa Fichele; Ignazio Senatore; Margherita Casiello; Giovanni Muscettola
Journal:  Psychiatry Res       Date:  2006-04-19       Impact factor: 3.222

2.  Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin.

Authors:  N Perwitz; M Fasshauer; J Klein
Journal:  Horm Metab Res       Date:  2006-05       Impact factor: 2.936

3.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 4.  Eating disorders: progress and problems.

Authors:  B T Walsh; M J Devlin
Journal:  Science       Date:  1998-05-29       Impact factor: 47.728

5.  Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol.

Authors:  Aaron N A Verty; Iain S McGregor; Paul E Mallet
Journal:  Neuropharmacology       Date:  2005-08-11       Impact factor: 5.250

6.  Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.

Authors:  D T Malone; D A Taylor
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

7.  Fenfluramine treatment in female rats accelerates the weight loss associated with activity-based anorexia.

Authors:  Deann P D Atchley; Lisa A Eckel
Journal:  Pharmacol Biochem Behav       Date:  2004-12-19       Impact factor: 3.533

8.  Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders.

Authors:  Helge Frieling; Heidi Albrecht; Sabine Jedtberg; Andreas Gozner; Bernd Lenz; Julia Wilhelm; Thomas Hillemacher; Martina de Zwaan; Johannes Kornhuber; Stefan Bleich
Journal:  Psychoneuroendocrinology       Date:  2008-11-28       Impact factor: 4.905

9.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.

Authors:  Tim C Kirkham; Claire M Williams; Filomena Fezza; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

10.  Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

Authors:  J E Beal; R Olson; L Laubenstein; J O Morales; P Bellman; B Yangco; L Lefkowitz; T F Plasse; K V Shepard
Journal:  J Pain Symptom Manage       Date:  1995-02       Impact factor: 3.612

View more
  24 in total

Review 1.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 2.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

3.  Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet.

Authors:  Virginia Mela; Fabiana Piscitelli; Alvaro Llorente Berzal; Julie Chowen; Cristoforo Silvestri; Maria Paz Viveros; Vincenzo Di Marzo
Journal:  J Physiol Biochem       Date:  2017-03-23       Impact factor: 4.158

4.  Diet-Induced Obesity in Cannabinoid-2 Receptor Knockout Mice and Cannabinoid Receptor 1/2 Double-Knockout Mice.

Authors:  Omayma Alshaarawy; Emily Kurjan; Nguyen Truong; L Karl Olson
Journal:  Obesity (Silver Spring)       Date:  2019-01-30       Impact factor: 5.002

5.  The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats.

Authors:  Sean B Ogden; Michael S Malamas; Alexandros Makriyannis; Lisa A Eckel
Journal:  Br J Pharmacol       Date:  2019-09-06       Impact factor: 8.739

6.  The Role of Mesolimbic Reward Neurocircuitry in Prevention and Rescue of the Activity-Based Anorexia (ABA) Phenotype in Rats.

Authors:  Claire J Foldi; Laura K Milton; Brian J Oldfield
Journal:  Neuropsychopharmacology       Date:  2017-03-21       Impact factor: 7.853

7.  Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia.

Authors:  Maria Scherma; Valentina Satta; Roberto Collu; Maria Francesca Boi; Paolo Usai; Walter Fratta; Paola Fadda
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

8.  Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018.

Authors:  Benjamin M Ford; Christian V Cabanlong; Sherrica Tai; Lirit N Franks; Narsimha R Penthala; Peter A Crooks; Paul L Prather; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2019-03-04       Impact factor: 4.030

Review 9.  Sex differences in cannabinoid-regulated biology: A focus on energy homeostasis.

Authors:  Edward J Wagner
Journal:  Front Neuroendocrinol       Date:  2016-01-19       Impact factor: 8.606

10.  Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial.

Authors:  Alin Andries; Bibi Gram; René Klinkby Støving
Journal:  Eat Weight Disord       Date:  2014-06-03       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.